Analysis – Goldea Capital

Lexis+ with Protégé is Now Purpose-Built AI for In-House Legal and Compliance Teams

Written by Customer Service on July 8, 2026. Posted in Mergers And Acquisitions.

New AI capabilities automate routine legal work and enable in-house teams to focus on strategic advisory, risk mitigation, and business collaboration NEW YORK, July 08, 2026 (GLOBE NEWSWIRE) — LexisNexis® Legal & Professional today announced private, secure, authoritative legal AI designed specifically for in-house legal and compliance teams, available in Lexis+® with Protégé™. The fully integrated platform powers the use of AI in the day-to-day experiences for in-house attorneys, paralegals, legal operations professionals, and compliance officers – freeing them to focus their time on higher-value activities such as advising the business, proactively mitigating risk, and collaborating more effectively across the organization. “In-house teams operate under unique pressures that cut across legal and business demands...

VitalEdge Technologies Acquires LHP Telematics to Expand Machine Intelligence for Heavy Equipment Dealers

Written by Customer Service on July 8, 2026. Posted in Mergers And Acquisitions.

Acquisition adds connected equipment data, fleet visibility, and telematics capabilities to VitalEdge’s purpose-built dealer technology platform CARY, N.C., July 08, 2026 (GLOBE NEWSWIRE) — VitalEdge Technologies, the leading provider of dealer management solutions for the heavy equipment industry, today announced the acquisition of LHP Telematics, a provider of industrial telematics solutions for connected equipment, rental fleets, OEMs, and mixed-fleet operations. The acquisition expands VitalEdge’s ability to help equipment dealers connect critical dealership operations with machine-level data, including location, utilization, meter readings, engine hours, fault codes, and asset-health signals. For dealers managing large equipment fleets across construction, rental, agriculture, material handling, and other equipment-intensive...

Eagle Real Estate Partners and The Vistria Group Acquire 402-Unit Orange County Apartment Community

Written by Customer Service on July 8, 2026. Posted in Mergers And Acquisitions.

Acquisition Preserves and Expands Long-Term Affordability Across Half of the Garden Grove Community in Supply-Constrained Orange County GARDEN GROVE, Calif., July 08, 2026 (GLOBE NEWSWIRE) — Eagle Real Estate Partners (“Eagle”), a vertically integrated multifamily investment manager and operator focused on attainable housing, and The Vistria Group (“Vistria”), a private investment firm that seeks to deliver both strong financial returns and meaningful impact, today announced the closing of an affordable housing preservation acquisition of Crystal View Apartments, a 402-unit apartment mixed-income workforce housing community located in Garden Grove, California. Through the acquisition, Eagle and Vistria will extend existing affordability for 20% of the community’s units restricted to households earning up to 50% of Area Median Income...

Nocera Expands Diversified Technology Strategy With Binding Agreement to Acquire an Equity Interest in INERGX, an Integrated Energy Storage and Power Platform for AI, Defense and Mission-Critical Demand

Written by Customer Service on July 8, 2026. Posted in Mergers And Acquisitions.

Investment Positions Nocera at the Intersection of the Global AI and Energy Infrastructure Build-Out, a Market Projected to Approach $7 Trillion by 2030 TAIPEI, Taiwan, July 08, 2026 (GLOBE NEWSWIRE) — Nocera, Inc. (NASDAQ: NCRA) (“Nocera” or the “Company”) today announced that it has entered into a binding agreement to acquire an equity interest in INERGX, an integrated energy storage and power platform being built to design, deploy and service mission-critical power and battery energy-storage systems supporting AI data centers, defense, industrial operations and critical infrastructure. Through this investment, Nocera is positioning itself at the intersection of one of the fastest-growing segments of the global AI infrastructure ecosystem, where reliable, scalable power has rapidly emerged as one of the defining constraints...

Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis

Written by Customer Service on July 8, 2026. Posted in Public Companies.

Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI Network Medicine platform designed to reduce risk and significantly increase the probability of clinical success Scipher’s AI Network Medicine platform identified CCL24 as a top-ranked therapeutic target for RA and used its proprietary data to identify a potential therapeutic response signature intended to support the selection of RA patients who potentially could benefit from treatment with nebokitug Phase 2 RA clinical study expected to read out in H1 2028, providing a potential key inflection point Combined company has multiple opportunities to create value for stakeholders, including the development of nebokitug as potentially the first precision medicine...

Conavi Medical Announces JSCAI Publication Demonstrating the Clinical Utility of Hybrid IVUS OCT Imaging

Written by Customer Service on July 8, 2026. Posted in Public Companies.

Publication demonstrates how complementary IVUS and OCT information supports lesion assessment, treatment planning, and stent optimization while helping manage contrast use TORONTO, July 08, 2026 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced the publication of a case report in the Journal of the Society for Cardiovascular Angiography & Interventions (“JSCAI”) titled “Versatility of Hybrid OCT and IVUS Imaging Enhances Contrast-Sparing Management of Eruptive Calcified Nodules.” The publication features Conavi’s hybrid intravascular ultrasound (“IVUS”) and optical coherence tomography (“OCT”)...

Odysight.ai Receives Purchase Order from Elbit Systems on Behalf of the Israeli Ministry of Defense for Deployment of Its Vision-Based Prognostics and Health Management System

Written by Customer Service on July 8, 2026. Posted in Public Companies.

The purchase order, valued at approximately $0.3 million (NIS 1.0 million), expands Odysight.ai’s operational portfolio and may lead to wide deployment across the Israeli Defense Forces upon successful completion Ramat Gan, Israel, July 08, 2026 (GLOBE NEWSWIRE) — Odysight.ai Inc. (NASDAQ/TASE: ODYS), a leader in AI-powered visual sensing and predictive maintenance (PdM) solutions for the defense, and industrial markets, today announced that it has received a purchase order from Elbit Systems, on behalf of the Israeli Ministry of Defense (IMOD), to integrate Odysight.ai’s computer vision-based Prognostics and Health Management (PHM) system onto several platforms. The order, valued at approximately $0.3 million (NIS 1.0 million), may lead the deployment across broader Israeli Defense Forces platforms, upon successful completion...

CorVel Named 2026 PropertyCasualty360 Insurance Luminaries Winner for Excellence in Claims Management

Written by Customer Service on July 8, 2026. Posted in Public Companies.

FORT WORTH, Texas, July 08, 2026 (GLOBE NEWSWIRE) — CorVel Corporation (NASDAQ: CRVL), a national provider of risk management solutions, today announced it has been named a 2026 PropertyCasualty360 Insurance Luminaries winner in the Excellence in Claims Management category. The award recognizes organizations that demonstrate outstanding claims expertise, operational discipline, technology innovation, and measurable client outcomes while advancing the property and casualty insurance industry. CorVel was recognized for its integrated approach to claims management, bringing together clinical expertise, operational excellence, and proprietary technology to help clients improve outcomes while reducing claim costs and complexity. Built on its proprietary CareMC platform and reinforced through the Company’s Operational Excellence...

BiomX Signs Non-Binding Letter of Intent to Acquire Control of Revenue-Generating Security Infrastructure and Systems Integration Company, Expanding Its Security Platform with Critical Infrastructure and Secure-Site Integration Capabilities

Written by Customer Service on July 8, 2026. Posted in Mergers And Acquisitions.

Proposed acquisition of an Israeli company with approximately 20 years of operating experience is expected to strengthen BiomX’s Detection-Analysis-Response strategy through security systems, fire detection, access control, intrusion detection, building-control, electrical infrastructure and secure-site integration capabilities NETANYA, Israel, July 08, 2026 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a company focused on acquiring and further developing technologies that identify, analyze, protect against and support faster responses to physical threats, today announced that its wholly owned subsidiary BiomX Israel Defense and Security Ltd. has signed a non-binding letter of intent (the “LOI”) to acquire a 60% controlling interest in Tsoock Defense Technologies...

Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors

Written by Customer Service on July 8, 2026. Posted in Public Companies.

BOSTON, July 08, 2026 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Jeremy Bender, Ph.D., M.B.A., to its Board of Directors. “I am thrilled to welcome Jeremy to our Board of Directors and excited to be working alongside him again,” said Natalie Holles, Chief Executive Officer of Aura Biosciences. “Jeremy is an accomplished biotechnology leader with deep experience advancing innovative therapies through late-stage development, commercialization and significant value creation in rare oncology. As Aura advances toward potential regulatory approval of bel-sar and prepares for its next phase of growth, his operational and commercial expertise will further strengthen...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals